Pebrilzo (pertuzumab)
- Region
- 🇺🇸 US
- Active substance
- pertuzumab
- Company
- Biocon Biologics Inc
- Status
- Approved
- FDA approval
- Thu 12 Nov 2026
- Designations
- New biologic
- Application
- BLA761501
- Official record
- www.accessdata.fda.gov
Regulatory milestones
FDA approves Pebrilzo (pertuzumab), a new medicine
Biocon Biologics Inc; BLA761501; New biologic; solution · source
In-depth analysis
Where it stands
Pebrilzo (pertuzumab), from Biocon Biologics Inc, is recorded as approved in the US. The FDA approval is dated 2026-11-12 under BLA761501, and the product is a solution. The milestone is marked as an official source.
In the EU, the records show Pebrilzo at the 'Opinion' stage. No CHMP opinion date is given, so the timing and content of that opinion cannot be confirmed from these records. The records contain no indication wording and no therapeutic area, so the approved use cannot be described here.
Pertuzumab is already well represented in the records. Perjeta, Phesgo and Poherdy are listed as authorised in the EU, and Poherdy is also listed as approved in the US. Pebrilzo is therefore not the first product with this substance in either region. The records do not describe how these products relate to one another, for example as reference product, biosimilar or combination.
Regulatory pathway and designations
The only designation recorded is 'New biologic', and the application is BLA761501. The records do not say whether the filing was a standalone BLA or an abbreviated biosimilar application. They also do not say whether any expedited programme, orphan status or other special designation applied, so none should be assumed.
In the US, a biologic is approved by the FDA through a Biologics License Application. The approval date is the point at which the product may be marketed under its labelling. The records give no review timeline, PDUFA goal date or advisory committee information.
In the EU, the 'Opinion' status means the CHMP has reached a view, but this is not itself a marketing authorisation. The European Commission decision follows the opinion. The records do not show whether that decision has been issued.
Safety and pharmacovigilance
The records contain no safety information. They give no label warnings, boxed warning, risk management commitments, post-marketing requirements or adverse event data for Pebrilzo, so no safety assessment can be made here.
As a general point, any newly approved biologic enters routine post-marketing pharmacovigilance. This includes spontaneous adverse event reporting and monitoring of the product's risk profile once it is in wider use. Whether any additional measures apply to Pebrilzo can only be confirmed from the approved US prescribing information and the corresponding EU documents.
What to watch
The first item is the EU outcome. Watch for the CHMP opinion details for Pebrilzo and the subsequent European Commission decision. The records give neither the opinion date nor any decision.
The second item is the US documentation. The approved prescribing information, the review documents and the approval letter would show the indication, any post-marketing commitments and any labelling differences from other pertuzumab products. None of these are in the records.
Finally, the records do not cover launch timing, availability or commercial plans, so these cannot be assessed. With several pertuzumab-containing products already approved, how Pebrilzo is positioned relative to them would need to be established from primary regulatory sources.
AI-generated on 2026-11-19 from the official records on this page (model claude-sonnet-5-5). It can contain errors: check the sources.
Same substance in other markets
- 🇪🇺 Phesgo Authorised · Roche Registration GmbH
- 🇺🇸 Poherdy Approved · Shanghai Henlius Biotech
- 🇪🇺 Poherdy Authorised · Organon N.V.
- 🇪🇺 Pebrilzo Opinion · Biosimilar Collaborations Ireland Limited
- 🇪🇺 Perjeta Authorised · Roche Registration GmbH
Follow Pebrilzo
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.